Oruka Therapeutics (ORKA) shares surged over 20% Monday, targeting their best single-day gain in a month after positive Phase 2a trial results for psoriasis therapy ORKA-001. 40 of 63 participants in the EVERLAST-A trial met the primary endpoint. BTIG hiked its price target by 94% to $151, citing once-yearly maintenance potential, while Guggenheim sees peak sales reaching $7 billion.